AsianScientist (Jun 2, 2014) – Japanese drug manufacturer, Eisai Co., Ltd. and its research and development subsidiary KAN Research Institute, Inc. (KRI) have officially commenced full-scale operation of their new research facility in Kobe, Hyogo prefecture.
KRI conducts discovery research based on the concept of “Integrative Cell Biology for Medicine” in its three areas of therapeutic focus – refractory immune diseases, neurodegenerative diseases and cancer relapse and metastasis, focusing on biologic therapies such as antibodies.
The new research facility, located within the Kobe Biomedical Innovation Cluster, has a total floor space of approximately 12,000m2, or roughly five times that of its previous premises; and the capacity to house around 100 researchers, more than twice the present number. In addition, laboratory specifications allow for the future installation of an antibody-drug conjugate (ADC) production facility and collaborative lab spaces for external academic and medical researchers, strengthening KRI’s antibody research capability while further promoting its open innovation initiatives through external partnerships, one of the core strategies of KRI.
These key features of the KRI’s new research facility will also contribute to the acceleration of the product creation activities of Eisai as a whole, incorporating state-of-the-art technologies such as those using antibodies and iPS cells into its research. Furthermore, the facility is designed to support business contingency plans in case of a crisis, as it is built using seismic isolation construction methods and is equipped with an emergency electricity generator that can run for up to 72 hours.
——-
Source: Eisai.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
